A Phase 2b study in patients with type 2 diabetes (T2DM) was completed for what looks likely to be the first oral form of insulin (ORMD-0801). The developing company, Oramed Pharmaceuticals’, CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study discuss the results. Read more